We are live on ! Find out more
TCM

Tekla Capital Management Portfolio holdings

AUM $2.56B
1-Year Est. Return 18.15%
This Fund
S&P 500
This Quarter Est. Return
-2.75%
1 Year Est. Return
+18.15%
3 Year Est. Return
+62.51%
5 Year Est. Return
+140.53%
10 Year Est. Return
+502.91%
AUM
$2.85B
AUM Growth
-$260M
Cap. Flow
-$71.1M
Cap. Flow %
-2.5%
Top 10 Hldgs %
35.96%
Holding
185
New
14
Increased
26
Reduced
26
Closed
10

Top Buys

Rank Stock Value
1
AZN icon
AstraZeneca
AZN
+$12.2M
2
SYK icon
Stryker
SYK
+$10.9M
3
XBI icon
State Street SPDR S&P Biotech ETF
XBI
+$8.83M
4
VRTX icon
Vertex Pharmaceuticals
VRTX
+$8.51M
5
BDX icon
Becton Dickinson
BDX
+$8.08M

Top Sells

Rank Stock Value
1
MRNA icon
Moderna
MRNA
+$36.7M
2
TMO icon
Thermo Fisher Scientific
TMO
+$31.4M
3
MRK icon
Merck
MRK
+$16.8M
4
ARNA
Arena Pharmaceuticals Inc
ARNA
+$16.4M
5
DHR icon
Danaher
DHR
+$14.7M

Sector Composition

Rank Sector Weight
1 Healthcare 95.64%
2 Real Estate 3.21%
3 Industrials 0.19%
Name Market Value Portfolio Weight Shares or Principal Change
in Stake 		Capital Flow
CCXI
126
DELISTED
ChemoCentryx, Inc.
CCXI
$1.96M 0.07%
78,197
– –
ZLAB icon
127
Zai Lab
ZLAB
$2.07B
$1.9M 0.07%
43,300
– –
FULC icon
128
Fulcrum Therapeutics
FULC
$288M
$1.83M 0.06%
77,293
– –
ACAD icon
129
Acadia Pharmaceuticals
ACAD
$4.93B
$1.75M 0.06%
72,225
– –
MREO
130
Mereo BioPharma
MREO
$48.4M
$1.74M 0.06%
1,551,082
– –
MEDP icon
131
Medpace
MEDP
$16.4B
$1.54M 0.05%
9,435
-9,436
-50% -$1.56M
STVN icon
132
Stevanato
STVN
$5.49B
$1.43M 0.05%
+71,190
New +$1.24M
MORF
133
DELISTED
Morphic Holding, Inc. Common Stock
MORF
$1.41M 0.05%
35,025
– –
SRRK icon
134
Scholar Rock
SRRK
$5.74B
$1.4M 0.05%
108,833
– –
ITOS
135
DELISTED
iTeos Therapeutics
ITOS
$1.36M 0.05%
42,362
– –
STRO icon
136
Sutro Biopharma
STRO
$416M
$1.35M 0.05%
16,392
-16,393
-50% -$1.56M
HARP
137
DELISTED
Harpoon Therapeutics, Inc. Common Stock
HARP
$1.29M 0.05%
+25,991
New +$1.35M
ACET icon
138
Adicet Bio
ACET
$85.6M
$1.26M 0.04%
3,958
– –
FATE icon
139
Fate Therapeutics
FATE
$303M
$1.23M 0.04%
31,652
-41,075
-56% -$1.59M
ASRT
140
DELISTED
Assertio
ASRT
$1.18M 0.04%
27,372
– –
THRX
141
DELISTED
Theseus Pharmaceuticals, Inc. Common Stock
THRX
$1.15M 0.04%
100,000
– –
DHC
142
Diversified Healthcare Trust
DHC
$2.22B
$1.15M 0.04%
357,720
– –
ENDP
143
DELISTED
Endo International plc
ENDP
$1.14M 0.04%
494,607
– –
ALXO icon
144
ALX Oncology
ALXO
$258M
$1.12M 0.04%
66,211
– –
DSGN icon
145
Design Therapeutics
DSGN
$849M
$1.05M 0.04%
65,351
– –
CYH icon
146
Community Health Systems
CYH
$416M
$1.05M 0.04%
88,335
– –
SNDX icon
147
Syndax Pharmaceuticals
SNDX
$1.77B
$982K 0.03%
+56,480
New +$951K
BEAM icon
148
Beam Therapeutics
BEAM
$2.78B
$906K 0.03%
15,817
– –
ICPT
149
DELISTED
Intercept Pharmaceuticals, Inc.
ICPT
$847K 0.03%
52,067
– –
RXDX
150
DELISTED
Prometheus Biosciences, Inc. Common Stock
RXDX
$835K 0.03%
+22,115
New +$874K
4 5
6
7 8

Similar funds

EST
EA Series Trust Havertown, Pennsylvania $2.84B AUM
VIA
Vident Investment Advisory Alpharetta, Georgia $2.9B AUM 24.67% 1-Year Est. Return
AWS
AJ Wealth Strategies New York $2.07B AUM 10.86% 1-Year Est. Return
JP
Jana Partners New York $1.34B AUM 4.95% 1-Year Est. Return
VCM
Vigilant Capital Management Portland, Maine $1.34B AUM 15.33% 1-Year Est. Return
FCFS
First Command Financial Services Fort Worth, Texas $1.06B AUM 10.74% 1-Year Est. Return
FCB
First Command Bank Fort Worth, Texas $1.06B AUM 10.74% 1-Year Est. Return
BWM
BerganKDV Wealth Management Bloomington, Minnesota $1,000M AUM 9.95% 1-Year Est. Return

Tekla Capital Management's Q1 2022 Portfolio in Review

As of Q1 2022, Tekla Capital Management held 185 positions worth $2.85B, down 8.4% from $3.11B the previous quarter. Its ten largest holdings account for 36% of the portfolio.

Tekla Capital Management's Q1 2022 filing shows 14 new, 26 increased, 26 reduced and 10 closed positions. Its largest new stake was State Street SPDR S&P Biotech ETF: 95,649 shares worth $8.6M. The largest sale was Moderna, an estimated $36.7M.

By sector, the portfolio is most concentrated in Healthcare at 96% of assets, down from 96% a quarter earlier, followed by Real Estate and Industrials.

  • Tekla Capital Management's largest Q1 2022 buy was State Street SPDR S&P Biotech ETF: 95,649 shares worth $8.6M.
  • Tekla Capital Management added most to AstraZeneca in Q1 2022, an estimated $12.2M increase.
  • Tekla Capital Management's biggest Q1 2022 reduction was Moderna, cutting an estimated $36.7M.
  • Tekla Capital Management fully exited Arena Pharmaceuticals Inc in Q1 2022, selling an estimated $16.4M.
  • Tekla Capital Management's ten largest holdings make up 36% of its $2.85B portfolio in Q1 2022.
  • Tekla Capital Management opened 14 new positions and closed 10 in Q1 2022.
  • Tekla Capital Management's portfolio value fell 8.4% quarter-over-quarter to $2.85B.

Based on Tekla Capital Management's 13F filing for Q1 2022, filed 13 May 2022.